Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATAI NASDAQ:ATYR NASDAQ:JMAC NASDAQ:RNAC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATAIatai Life Sciences$3.23+15.8%$2.30$1.03▼$3.35$647.09M1.442.19 million shs14.88 million shsATYRaTyr Pharma$5.99+3.5%$4.82$1.58▼$6.44$533.13M0.891.38 million shs5.07 million shsJMACMaxpro Capital Acquisition$6.21-3.7%$6.18$7.50▼$19.22$83.39M0.0174,040 shs14,775 shsRNACCartesian Therapeutics$11.84-5.5%$10.67$8.46▼$26.50$307.30M0.3697,508 shs61,404 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATAIatai Life Sciences+15.77%+23.28%+38.63%+119.73%+101.88%ATYRaTyr Pharma+3.45%+13.02%+15.86%+93.23%+254.44%JMACMaxpro Capital Acquisition+7.32%+13.16%+1.49%+8.40%+3,093.07%RNACCartesian Therapeutics-5.51%-11.11%+18.40%+12.76%-35.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATAIatai Life Sciences3.2105 of 5 stars3.84.00.00.02.31.70.6ATYRaTyr Pharma2.2627 of 5 stars3.61.00.00.02.51.70.6JMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ARNACCartesian Therapeutics2.3479 of 5 stars3.41.00.00.02.83.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATAIatai Life Sciences 3.50Strong Buy$9.00178.64% UpsideATYRaTyr Pharma 3.14Buy$20.20237.23% UpsideJMACMaxpro Capital Acquisition 0.00N/AN/AN/ARNACCartesian Therapeutics 2.83Moderate Buy$40.00237.84% UpsideCurrent Analyst Ratings BreakdownLatest JMAC, ATYR, ATAI, and RNAC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2025RNACCartesian TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.007/2/2025ATAIatai Life SciencesAegisSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/2/2025ATAIatai Life SciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $12.006/20/2025ATYRaTyr PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$17.00 ➝ $25.006/4/2025ATYRaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.005/20/2025ATAIatai Life SciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$5.005/20/2025ATAIatai Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/19/2025ATYRaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00 ➝ $35.005/13/2025ATAIatai Life SciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/8/2025RNACCartesian TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$41.00 ➝ $40.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATAIatai Life Sciences$310K2,087.41N/AN/A$0.69 per share4.68ATYRaTyr Pharma$230K2,317.87N/AN/A$0.83 per share7.22JMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/ARNACCartesian Therapeutics$38.91M7.90N/AN/A($0.27) per share-43.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATAIatai Life Sciences-$149.27M-$0.91N/AN/AN/AN/A-102.10%-77.55%8/12/2025 (Estimated)ATYRaTyr Pharma-$64.02M-$0.810.00N/AN/AN/A-87.09%-64.77%8/12/2025 (Estimated)JMACMaxpro Capital AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ARNACCartesian Therapeutics-$77.42M-$52.830.00N/AN/AN/AN/A-7.01%8/6/2025 (Estimated)Latest JMAC, ATYR, ATAI, and RNAC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025N/ARNACCartesian Therapeutics-$0.77N/AN/AN/A$0.77 millionN/A8/12/2025Q2 2025ATAIatai Life Sciences-$0.13N/AN/AN/AN/AN/A8/12/2025Q2 2025ATYRaTyr Pharma-$0.18N/AN/AN/AN/AN/A5/14/2025Q1 2025ATAIatai Life Sciences-$0.19-$0.15+$0.04-$0.15N/A$1.56 million5/8/2025Q1 2025RNACCartesian Therapeutics-$0.61-$0.68-$0.07-$0.68$0.69 million$1.10 million5/7/2025Q1 2025ATYRaTyr Pharma-$0.19-$0.17+$0.02-$0.17N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATAIatai Life SciencesN/AN/AN/AN/AN/AATYRaTyr PharmaN/AN/AN/AN/AN/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/ARNACCartesian TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATAIatai Life Sciences0.084.074.07ATYRaTyr Pharma0.017.797.79JMACMaxpro Capital AcquisitionN/AN/AN/ARNACCartesian TherapeuticsN/A12.3412.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATAIatai Life Sciences28.41%ATYRaTyr Pharma61.72%JMACMaxpro Capital Acquisition73.18%RNACCartesian Therapeutics86.95%Insider OwnershipCompanyInsider OwnershipATAIatai Life Sciences26.80%ATYRaTyr Pharma3.70%JMACMaxpro Capital Acquisition19.27%RNACCartesian Therapeutics60.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATAIatai Life Sciences80200.34 million146.65 millionOptionableATYRaTyr Pharma5389.00 million85.71 millionOptionableJMACMaxpro Capital Acquisition2,02113.43 million10.84 millionNot OptionableRNACCartesian Therapeutics6425.95 million10.30 millionOptionableJMAC, ATYR, ATAI, and RNAC HeadlinesRecent News About These CompaniesQ2 Earnings Forecast for RNAC Issued By WedbushJuly 13, 2025 | americanbankingnews.comCartesian Therapeutics (NASDAQ:RNAC) Coverage Initiated by Analysts at WedbushJuly 12, 2025 | americanbankingnews.comBrokers Set Expectations for RNAC Q2 EarningsJuly 11, 2025 | marketbeat.comWedbush Initiates Coverage of Cartesian Therapeutics (RNAC) with Outperform RecommendationJuly 9, 2025 | msn.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 9, 2025 | marketbeat.comCartesian Therapeutics (NASDAQ:RNAC) Earns Outperform Rating from Analysts at WedbushJuly 9, 2025 | marketbeat.comWe're Not Very Worried About Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn RateJune 21, 2025 | finance.yahoo.comCartesian Therapeutics holds annual stockholders meetingJune 17, 2025 | investing.comCartesian Therapeutics Announces New Employment Inducement GrantsJune 3, 2025 | globenewswire.comBTIG Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)June 2, 2025 | theglobeandmail.comCartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia GravisMay 30, 2025 | globenewswire.comCartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQMay 13, 2025 | manilatimes.netMAnalysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), Cartesian Therapeutics (RNAC)May 11, 2025 | theglobeandmail.comCartesian Therapeutics (RNAC) Gets a Buy from Mizuho SecuritiesMay 11, 2025 | theglobeandmail.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Just Released Its First-Quarter Results And Analysts Are Updating Their EstimatesMay 11, 2025 | finance.yahoo.comCartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 8, 2025 | globenewswire.comWhy Cartesian Therapeutics, Inc. (RNAC) is Among the Best Small Cap Stocks to Buy with the Biggest Upside PotentialMay 5, 2025 | insidermonkey.comCartesian Therapeutics Announces New Employment Inducement GrantsMay 2, 2025 | globenewswire.comCartesian Therapeutics management to meet with BTIGApril 26, 2025 | markets.businessinsider.comWhy Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Down 5.62%April 22, 2025 | aaii.comAWhy Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Down 6.62%April 15, 2025 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeJMAC, ATYR, ATAI, and RNAC Company Descriptionsatai Life Sciences NASDAQ:ATAI$3.23 +0.44 (+15.77%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$3.32 +0.09 (+2.79%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.aTyr Pharma NASDAQ:ATYR$5.99 +0.20 (+3.45%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$6.16 +0.18 (+2.92%) As of 07/18/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.Maxpro Capital Acquisition NASDAQ:JMAC$6.21 -0.24 (-3.72%) As of 07/18/2025Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.Cartesian Therapeutics NASDAQ:RNAC$11.84 -0.69 (-5.51%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$12.15 +0.31 (+2.62%) As of 07/18/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.